demonstrated expression of gp130 [a subunit of the IL-6-receptor (IL-6R)] on the tumour cells of 77/114 (67.5%) patients with DLBCL, with a higher frequency of IL-6R expression on tumours with an activated B-cell COO (Hashwah et al., 2019). This evidence concerns the gene IL6R and diffuse large B-cell lymphoma.